$MRK News
10 Nasdaq stocks with returns of at least 240% in 2014 5:38 p.m. Sept. 11, 2014 - Philip van Doorn
FDA approves Merck's new-kind of cancer drug 2:57 p.m. Sept. 4, 2014 - MarketWatch.com
Merck rises 1.2% to lead Dow gainers 9:32 a.m. Aug. 13, 2014 - MarketWatch
Newscast: 20 firms with fat profits pay no taxes 5:44 a.m. Aug. 13, 2014 - MarketWatch
Merck net falls 4%; confirms full-year outlook 2:30 a.m. Aug. 13, 2014 - MarketWatch.com
Australia's CSL considers bigger stock buyback 7:35 p.m. Aug. 12, 2014 - MarketWatch.com
Zoetis narrows full-year earnings guidance 8:12 a.m. Aug. 5, 2014 - MarketWatch.com
Video chat: How have corporate earnings done so far? 12:51 p.m. July 31, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 9:01 p.m. July 29, 2014 - MarketWatch
U.S. stocks end choppy trade lower 4:16 p.m. July 29, 2014 - Carla Mozee
Herbalife sinks on disappointing results; Darden gains 3:16 p.m. July 29, 2014 - Angela Johnson
Why short-sellers are winning right now and going big against Ackman's 'deathblow' 9:03 a.m. July 29, 2014 - blogs.marketwatch.com
Newscast: Wall Street may gain ground 7:35 a.m. July 29, 2014 - MarketWatch
Merck profit up on one-time gain, lower costs 7:26 a.m. July 29, 2014 - MarketWatch.com
Merck shares rise in premarket trade as profit, sales beat forecasts 7:12 a.m. July 29, 2014 - Tomi Kilgore
Merck full-year adj. 2014 EPS target $3.43-$3.53 vs. FirstCall consensus $3.48 7:00 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 FactSet sales consensus $10.59 bln 6:59 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 sales $10.934 bln vs. $11.01 bln a year ago 6:59 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 EPS 68 cents vs. 30 cents a year ago 6:58 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 adj. EPS 85 cents vs. First Call EPS consensus 81 cents 6:58 a.m. July 29, 2014 - Tomi Kilgore
Unilife: A Medical Device Company Poised For Major Upside On New Revenue Streams 11:38 a.m. Sept. 19, 2014 - Seeking Alpha
Dow 30 Stock Roundup: Boeing to Receive $4.2B Contract from NASA, Cisco to Acquire Metacloud - Analyst Blog 10:40 a.m. Sept. 19, 2014 - Zacks.com
Stock Market News for September 19, 2014 - Market News 10:10 a.m. Sept. 19, 2014 - Zacks.com
Merck (MRK) On Momo Momentum Watch Today 9:49 a.m. Sept. 19, 2014 - TheStreet.com
EC clears Xultophy 7:18 a.m. Sept. 19, 2014 - Seeking Alpha
Big Pharma Might Finally Be Over the Alzheimer’s Hump 5:32 a.m. Sept. 19, 2014 - InvestorPlace.com
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog 4:55 p.m. Sept. 18, 2014 - Zacks.com
FDA clears Trulicity 4:03 p.m. Sept. 18, 2014 - Seeking Alpha
Roadmap Capital's Hugh Cleland And Stephen Ireland: Due Diligence Rules In Biotech Investment 3:08 p.m. Sept. 18, 2014 - Seeking Alpha
Bayer Moves Out of Material World 10:34 a.m. Sept. 18, 2014 - The Wall Street Journal Interactive Edition
Bayer to Seek Plastics IPO 8:44 a.m. Sept. 18, 2014 - The Wall Street Journal Interactive Edition
Credit Suisse Gold Standard Yield Stocks May Be the Safest to Own Now 7:20 a.m. Sept. 18, 2014 - 247WallSt.com
Rite Aid Stock a Sell on Deteriorating Fundamentals and Technicals 6:02 a.m. Sept. 18, 2014 - InvestorPlace.com
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog 7:15 p.m. Sept. 17, 2014 - Zacks.com
Roche CEO Rules Out Big Deals 10:29 a.m. Sept. 17, 2014 - The Wall Street Journal Interactive Edition
Merck once-weekly diabetes drug candidate successful in Phase 3 10:00 a.m. Sept. 17, 2014 - Seeking Alpha
Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Merck (MRK) Lags 10:00 a.m. Sept. 17, 2014 - TheStreet.com
Sun licenses Merck anti-inflammatory mAb 9:05 a.m. Sept. 17, 2014 - Seeking Alpha
Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes 8:34 a.m. Sept. 17, 2014 - benzinga.com
Bayer to Separate Plastics Unit 12:01 a.m. Sept. 17, 2014 - The Wall Street Journal Interactive Edition
Merck Animal Health to market Neogen's dairy genomic program 8:45 a.m. Sept. 18, 2014 - PR Newswire - PRF
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab 1:38 p.m. Sept. 17, 2014 - BusinessWire - BZX
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes 9:32 a.m. Sept. 17, 2014 - BusinessWire - BZX
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab 8:30 a.m. Sept. 17, 2014 - BusinessWire - BZX
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary 6:02 a.m. Sept. 17, 2014 - BusinessWire - BZX
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis 1:30 p.m. Sept. 15, 2014 - BusinessWire - BZX
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 9:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
BeiGene Receives Clinical Milestone Payment for Development of BGB-290 8:00 a.m. Sept. 15, 2014 - BusinessWire - BZX
U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment, an Industrial Info News Alert 6:31 a.m. Sept. 11, 2014 - Marketwire
Merck & Co.'s Keytruda is Approved in the United States for the Treatment of Advanced and Unresectable Malignant Melanoma 10:00 a.m. Sept. 10, 2014 - PR Newswire - PRF
Animal Antimicrobials and Antibiotics Market by Products (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides), Animals (Dog, Poultry, Swine), Mode Of Delivery (Premixes, Oral Powders and Solutions, Injections) - Global Forecasts to 2018 8:48 p.m. Sept. 9, 2014 - PR Newswire - PRF
Animal Parasiticides Market by Product (Endoparasiticides, Ectoparasiticides, Endectocides, Oral Liquids, Tablets, Injectables, Sprays, Pour On, Spot On, Collars, Ear Tags), Animal (Dogs, Cats, Cattle, Pigs, Sheep & Goats) - Global Forecast to 2018 6:51 p.m. Sept. 9, 2014 - PR Newswire - PRF
Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec 3:08 p.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O’Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO 8:15 p.m. Sept. 8, 2014 - BusinessWire - BZX
Merck to Participate at the Morgan Stanley Global Healthcare Conference 5:00 p.m. Sept. 8, 2014 - BusinessWire - BZX
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
FDA Approves Pembrolizumab for Advanced Melanoma 5:07 p.m. Sept. 4, 2014 - PR Newswire - PRF
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy 3:46 p.m. Sept. 4, 2014 - PR Newswire - PRF
MRA Applauds Latest Melanoma Drug Approval as “Major Breakthrough” 3:31 p.m. Sept. 4, 2014 - BusinessWire - BZX
10 Nasdaq stocks with returns of at least 240% in 2014 5:38 p.m. Sept. 11, 2014 - Philip van Doorn
FDA approves Merck's new-kind of cancer drug 2:57 p.m. Sept. 4, 2014 - MarketWatch.com
Merck rises 1.2% to lead Dow gainers 9:32 a.m. Aug. 13, 2014 - MarketWatch
Newscast: 20 firms with fat profits pay no taxes 5:44 a.m. Aug. 13, 2014 - MarketWatch
Merck net falls 4%; confirms full-year outlook 2:30 a.m. Aug. 13, 2014 - MarketWatch.com
Australia's CSL considers bigger stock buyback 7:35 p.m. Aug. 12, 2014 - MarketWatch.com
Zoetis narrows full-year earnings guidance 8:12 a.m. Aug. 5, 2014 - MarketWatch.com
Video chat: How have corporate earnings done so far? 12:51 p.m. July 31, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 9:01 p.m. July 29, 2014 - MarketWatch
U.S. stocks end choppy trade lower 4:16 p.m. July 29, 2014 - Carla Mozee
Herbalife sinks on disappointing results; Darden gains 3:16 p.m. July 29, 2014 - Angela Johnson
Why short-sellers are winning right now and going big against Ackman's 'deathblow' 9:03 a.m. July 29, 2014 - blogs.marketwatch.com
Newscast: Wall Street may gain ground 7:35 a.m. July 29, 2014 - MarketWatch
Merck profit up on one-time gain, lower costs 7:26 a.m. July 29, 2014 - MarketWatch.com
Merck shares rise in premarket trade as profit, sales beat forecasts 7:12 a.m. July 29, 2014 - Tomi Kilgore
Merck full-year adj. 2014 EPS target $3.43-$3.53 vs. FirstCall consensus $3.48 7:00 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 FactSet sales consensus $10.59 bln 6:59 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 sales $10.934 bln vs. $11.01 bln a year ago 6:59 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 EPS 68 cents vs. 30 cents a year ago 6:58 a.m. July 29, 2014 - Tomi Kilgore
Merck Q2 adj. EPS 85 cents vs. First Call EPS consensus 81 cents 6:58 a.m. July 29, 2014 - Tomi Kilgore
Unilife: A Medical Device Company Poised For Major Upside On New Revenue Streams 11:38 a.m. Sept. 19, 2014 - Seeking Alpha
Dow 30 Stock Roundup: Boeing to Receive $4.2B Contract from NASA, Cisco to Acquire Metacloud - Analyst Blog 10:40 a.m. Sept. 19, 2014 - Zacks.com
Stock Market News for September 19, 2014 - Market News 10:10 a.m. Sept. 19, 2014 - Zacks.com
Merck (MRK) On Momo Momentum Watch Today 9:49 a.m. Sept. 19, 2014 - TheStreet.com
EC clears Xultophy 7:18 a.m. Sept. 19, 2014 - Seeking Alpha
Big Pharma Might Finally Be Over the Alzheimer’s Hump 5:32 a.m. Sept. 19, 2014 - InvestorPlace.com
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog 4:55 p.m. Sept. 18, 2014 - Zacks.com
FDA clears Trulicity 4:03 p.m. Sept. 18, 2014 - Seeking Alpha
Roadmap Capital's Hugh Cleland And Stephen Ireland: Due Diligence Rules In Biotech Investment 3:08 p.m. Sept. 18, 2014 - Seeking Alpha
Bayer Moves Out of Material World 10:34 a.m. Sept. 18, 2014 - The Wall Street Journal Interactive Edition
Bayer to Seek Plastics IPO 8:44 a.m. Sept. 18, 2014 - The Wall Street Journal Interactive Edition
Credit Suisse Gold Standard Yield Stocks May Be the Safest to Own Now 7:20 a.m. Sept. 18, 2014 - 247WallSt.com
Rite Aid Stock a Sell on Deteriorating Fundamentals and Technicals 6:02 a.m. Sept. 18, 2014 - InvestorPlace.com
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog 7:15 p.m. Sept. 17, 2014 - Zacks.com
Roche CEO Rules Out Big Deals 10:29 a.m. Sept. 17, 2014 - The Wall Street Journal Interactive Edition
Merck once-weekly diabetes drug candidate successful in Phase 3 10:00 a.m. Sept. 17, 2014 - Seeking Alpha
Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Merck (MRK) Lags 10:00 a.m. Sept. 17, 2014 - TheStreet.com
Sun licenses Merck anti-inflammatory mAb 9:05 a.m. Sept. 17, 2014 - Seeking Alpha
Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes 8:34 a.m. Sept. 17, 2014 - benzinga.com
Bayer to Separate Plastics Unit 12:01 a.m. Sept. 17, 2014 - The Wall Street Journal Interactive Edition
Merck Animal Health to market Neogen's dairy genomic program 8:45 a.m. Sept. 18, 2014 - PR Newswire - PRF
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab 1:38 p.m. Sept. 17, 2014 - BusinessWire - BZX
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes 9:32 a.m. Sept. 17, 2014 - BusinessWire - BZX
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab 8:30 a.m. Sept. 17, 2014 - BusinessWire - BZX
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary 6:02 a.m. Sept. 17, 2014 - BusinessWire - BZX
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis 1:30 p.m. Sept. 15, 2014 - BusinessWire - BZX
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 9:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
BeiGene Receives Clinical Milestone Payment for Development of BGB-290 8:00 a.m. Sept. 15, 2014 - BusinessWire - BZX
U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment, an Industrial Info News Alert 6:31 a.m. Sept. 11, 2014 - Marketwire
Merck & Co.'s Keytruda is Approved in the United States for the Treatment of Advanced and Unresectable Malignant Melanoma 10:00 a.m. Sept. 10, 2014 - PR Newswire - PRF
Animal Antimicrobials and Antibiotics Market by Products (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides), Animals (Dog, Poultry, Swine), Mode Of Delivery (Premixes, Oral Powders and Solutions, Injections) - Global Forecasts to 2018 8:48 p.m. Sept. 9, 2014 - PR Newswire - PRF
Animal Parasiticides Market by Product (Endoparasiticides, Ectoparasiticides, Endectocides, Oral Liquids, Tablets, Injectables, Sprays, Pour On, Spot On, Collars, Ear Tags), Animal (Dogs, Cats, Cattle, Pigs, Sheep & Goats) - Global Forecast to 2018 6:51 p.m. Sept. 9, 2014 - PR Newswire - PRF
Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec 3:08 p.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O’Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO 8:15 p.m. Sept. 8, 2014 - BusinessWire - BZX
Merck to Participate at the Morgan Stanley Global Healthcare Conference 5:00 p.m. Sept. 8, 2014 - BusinessWire - BZX
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
FDA Approves Pembrolizumab for Advanced Melanoma 5:07 p.m. Sept. 4, 2014 - PR Newswire - PRF
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy 3:46 p.m. Sept. 4, 2014 - PR Newswire - PRF
MRA Applauds Latest Melanoma Drug Approval as “Major Breakthrough” 3:31 p.m. Sept. 4, 2014 - BusinessWire - BZX
